Scarica l'app Stockscreener
16.06
6.78%
1.02
Dopo l'orario di chiusura:
16.06
Hutchmed China Limited Adr Borsa (HCM) Ultime notizie
HUTCHMEDOncology portfolio growth expected to continue - Research Tree
HUTCHMED (China) Limited (NASDAQ:HCM) Shares Sold by Connor Clark & Lunn Investment Management Ltd. - Defense World
HUTCHMED Announces NMPA Conditional Approval for TAZVERIK® (tazemetostat) for the Treatment of Relapsed or Refractory Follicular Lymphoma - GlobeNewswire Inc.
HUTCHMED Highlights Savolitinib SAVANNAH Phase II and Other Data at European Lung Cancer Congress 2025 - GlobeNewswire
Innovent and HUTCHMED Jointly Announce that the FRUSICA-2 Phase 2/3 Study of Sintilimab and Fruquintinib Combination Has Met Its Primary Endpoint in Advanced Renal Cell Carcinoma in China - The Manila Times
HUTCHMED and Innovent Jointly Announce that the FRUSICA-2 - GlobeNewswire
International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on November 8th and 9th, 2023 - AsiaOne
HUTCHMED (HCM) Upgraded to Buy: Here's Why - Yahoo Finance
Wall Street Analysts Believe HUTCHMED (HCM) Could Rally 72.83%: Here's is How to Trade - Yahoo Finance
CN NMPA Guides Pharmas, Research Institutes to Enlarge R&D of Innovative Drugs, High-Quality Generic Drugs - AASTOCKS.com
ABC Arbitrage SA Buys New Holdings in HUTCHMED (China) Limited (NASDAQ:HCM) - MarketBeat
Crossmark Global Holdings Inc. Increases Stock Position in HUTCHMED (China) Limited (NASDAQ:HCM) - Defense World
CN Healthcare Fund Breaks even w/ Slim Surplus in 2024 - AASTOCKS.com
HUTCHMED Announces NMPA Full Approval for ORPATHYS® (savolitinib) in China for Patients with Locally Advanced or Metastatic MET Exon 14 NSCLC - GlobeNewswire
UBS Trims HUTCHMED (00013.HK)TP to $38.7 w/ Rating Buy - AASTOCKS.com
Private equity firms are HUTCHMED (China) Limited's (LON:HCM) biggest owners and were rewarded after market cap rose by UK£120m last week - Yahoo Finance
HSBC Global Research Prefers BeiGene/ SINO BIOPHARM/ HYGEIA HEALTH Given Higher Visibility in CN Pharma & Medical Device Subsectors - AASTOCKS.com
Hutchmed announces progress, hits milestone with lung cancer treatment - ShareCast
Market news - Research the market
Savolitinib Plus Osimertinib Receives Priority Review in China for Pretreated EGFR+ NSCLC With a MET Amplification - OncLive
HUTCHMED Announces NDA Acceptance in China with Priority Review Status for ORPATHYS® and TAGRISSO® Combination in Lung Cancer Patients with MET amplification After Progression on First-Line EGFR Inhibitor Therapy - The Manila Times
HUTCHMED Announces NDA Acceptance in China with Priority - GlobeNewswire
Jane Street Group LLC Raises Stock Holdings in HUTCHMED (China) Limited (NASDAQ:HCM) - Defense World
HUTCHMED (China) Limited (NASDAQ:HCM) Shares Purchased by State Street Corp - Defense World
HCMHUTCHMED (China) Limited American Depositary Shares Latest Stock News & Market Updates - StockTitan
HUTCHMED Announces Breakthrough Therapy Designation in China for ORPATHYS® and TAGRISSO® Combination in Certain Lung Cancer Patients After Disease Progression on EGFR Inhibitor Therapy - The Manila Times
HUTCHMED Announces Breakthrough Therapy Designation in - GlobeNewswire
Hutchmed endometrial cancer treatment gets conditional approval in China - ShareCast
M&G Plc Has $5.35 Million Holdings in HUTCHMED (China) Limited (NASDAQ:HCM) - MarketBeat
How Trump and Harris plan to address housing affordability - Yahoo Finance
Blue Trust Inc. Purchases 3,057 Shares of HUTCHMED (China) Limited (NASDAQ:HCM) - Defense World
HUTCHMED Announces that TAGRISSO® plus ORPATHYS® - GlobeNewswire
HUTCHMED Announces that TAGRISSO® plus ORPATHYS® demonstrated high, clinically meaningful - The Bakersfield Californian
HUTCHMED Announces that TAGRISSO® plus ORPATHYS® demonstrated high, clinically meaningful response rate in lung cancer patients with high levels of MET overexpression and/or amplification in SAVANNAH Phase II trial - Yahoo Finance UK
HUTCHMED (China) Ltd (HCM) (Q2 2024) Earnings Call Highlights: Strong US Sales Propel Growth ... - Yahoo Finance
FDA Approves 16 New Cancer Treatments As Global Cancer Rates Skyrocket - Barchart
Vanguard Personalized Indexing Management LLC Buys 1,168 Shares of HUTCHMED (China) Limited (NASDAQ:HCM) - Defense World
Rhumbline Advisers Boosts Stock Position in HUTCHMED (China) Limited (NASDAQ:HCM) - Defense World
Research Analysts Set Expectations for HUTCHMED (China) Limited’s FY2025 Earnings (NASDAQ:HCM) - Defense World
HUTCHMED (LON:HCM) Share Price Crosses Above 200 Day Moving Average of $284.47 - Defense World
Deutsche Bank ADR Virtual Investor Conference: Presentations Now Available for Online Viewing - Yahoo Finance
HUTCHMED Announces Japan Approval for FRUZAQLA® (fruquintinib) Received by Takeda - Yahoo Finance
CN National Reimbursement Drug List Raises Requirements on Innovative Drugs: Report - AASTOCKS.com
International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on September 24th and 25th, 2024 - Yahoo Finance
International companies to host live webcasts at Deutsche - GlobeNewswire
7 Best-Performing China Stocks for October 2024 - NerdWallet
HUTCHMED Voluntarily Withdraws Supplemental New Drug Application in China for Fruquintinib - AASTOCKS.com
Dr Mehta on the Sequencing of CAR T-Cell Therapy and Bispecific Antibodies in Lymphoma - OncLive
What Starbucks' new CEO must instantly do to address crisis - Yahoo Finance
CMBI Raises HUTCHMED (00013.HK) TP to $35.61; Fruquintinib's Overseas Sales Beat - AASTOCKS.com
HSI Closes Down 39 pts; CN Property & Car Stocks Wane; POWER ASSETS Rises 5% Against Mkt - AASTOCKS.com
1.48%
0.34%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):